Spots Global Cancer Trial Database for defactinib
Every month we try and update this database with for defactinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | NCT04331041 | Pancreas Cancer Cancer of the P... Pancreas Adenoc... | Adaptive stereo... Defactinib Tumor biopsy Research blood ... | 18 Years - | Washington University School of Medicine | |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | NCT02758587 | Carcinoma, Non-... Mesothelioma Pancreatic Neop... | Defactinib Pembrolizumab | 18 Years - | NHS Greater Glasgow and Clyde | |
| Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | NCT02546531 | Advanced Solid ... Solid Tumors Pancreatic Canc... | Defactinib Pembrolizumab Gemcitabine | 18 Years - | Washington University School of Medicine | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | NCT01778803 | Ovarian Cancer | defactinib Paclitaxel | 18 Years - | Verastem, Inc. | |
| Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | NCT01943292 | Non Hematologic... | Defactinib | 20 Years - | Verastem, Inc. | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I Trial of Defactinib and VS-6766. | NCT03875820 | NSCLC Low Grade Serou... Endometrioid Ca... Pancreatic Canc... | VS-6766 Defactinib | 18 Years - | Institute of Cancer Research, United Kingdom | |
| A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer | NCT05787561 | Mesonephric Gyn... | Avutometinib (V... Defactinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | NCT06072781 | Low Grade Serou... | avutometinib Defactinib Pegylated lipos... Paclitaxel Topotecan Letrozole Anastrozole | 18 Years - | Verastem, Inc. | |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | NCT01778803 | Ovarian Cancer | defactinib Paclitaxel | 18 Years - | Verastem, Inc. | |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | NCT02758587 | Carcinoma, Non-... Mesothelioma Pancreatic Neop... | Defactinib Pembrolizumab | 18 Years - | NHS Greater Glasgow and Clyde | |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | NCT03727880 | Resectable Panc... Pancreatic Duct... | Pembrolizumab Defactinib | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | NCT05512208 | Endometrioid Ca... Mucinous Ovaria... High Grade Sero... Cervical Cancer Solid Tumor | Avutometinib (V... | 18 Years - 99 Years | University of Oklahoma | |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | NCT05798507 | Glioblastoma Recurrent Gliob... | Avutometinib Biospecimen Col... Defactinib | 21 Years - | Emory University | |
| Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | NCT04331041 | Pancreas Cancer Cancer of the P... Pancreas Adenoc... | Adaptive stereo... Defactinib Tumor biopsy Research blood ... | 18 Years - | Washington University School of Medicine | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | NCT06369259 | Advanced Colore... | Defactinib Cetuximab Avutometinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | NCT06394804 | Low-Grade Serou... | Avutometinib Defactinib Letrozole | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pembrolizumab + Defactinib In Pleural Mesothelioma | NCT04201145 | Malignant Pleur... | Pembrolizumab Defactinib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | NCT03727880 | Resectable Panc... Pancreatic Duct... | Pembrolizumab Defactinib | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | NCT01943292 | Non Hematologic... | Defactinib | 20 Years - | Verastem, Inc. | |
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | NCT03287271 | Ovarian Cancer | VS-6063 Paclitaxel Carboplatin | 18 Years - | University of California, San Diego | |
| Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | NCT02758587 | Carcinoma, Non-... Mesothelioma Pancreatic Neop... | Defactinib Pembrolizumab | 18 Years - | NHS Greater Glasgow and Clyde |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
